Treatment of AKR cells that had spontaneously become producers of a murine leukemia virus with a partially purified mouse interferon (> 5 X 107 international mouse reference units per mg of protein)
Interferon is thought to inhibit virus replication by a complex mechanism. The optimal development of an intracellular antiviral state after interferon treatment takes several hours and is dependent on cell-directed RNA and protein synthesis. The existence' of this antiviral state gives rise to very few measurable changes in the metabolic qr physiologic state of the cells unless they are infected with an interferon-sensitive virus. In this case, the virus multiplies poorly compared to its replication in cells that had not been treated with interferon (1) . Most reports suggest that the basis for this interferoninduced inhibition of-virus replication is an inhibition of the transcription or translation of virus genetic information (2, 3) .
RNA tumor viruses are known to be sensitive to interferon (4) . During a series of studies on the effect of interferon on the replication of mouse leukemia viruses, however, we made the unexpected observation that interferon treatment markedly inhibited the replication of a murine leukemia virus (MLV) in AKR cells that spontaneously had become chronically infected by an endogenous .MLV several cell generations before the interferon treatment. In addition, this inhibitory effect did not appear to be the direct result of an inhibition of the translation of virus genetic information, since the intracellular level of viral group-specific (gs) antigens was increased in cells in which the release of infectious virus and of viral reverse transcriptase were inhibited.
MATERIALS AND METHODS
The AKR cells (here termed AKR,C-)' were supplied by Dr. W. Rowe. These were originally negative for virus production and negative for viral p30 (gs) antigen, and their culture fluids were negative for viral reverse transcriptase activity. These AKR,C-cells do, however, contain the AKR-murine sarcoma virus genome (5) . The cells (now termed AKR,C+) spontaneously became virus producers, and more than 85%o
were then positive for the virus group-specific antigens (gs-1 and gs-3) in an immunofluorescence assay. Type-C budding virus was easily detected when these cultures were examined by electron microscopy, and high titers of virus reverse transcriptase activity were found in AKR,C+ culture fluids ( Table 1) .
The interferon used was prepared by the method of Paucker, using an immunoadsorption step with antibody against mouse interferon prepared in rabbit (6 AKR cultures were treated with interferon and then washed as indicated in the legend to Table 1 . One-third of the cultures was infected 24, 48, or 72 hr after interferon treatment with VSV at a virus: cell multiplicity of about 10: 1. After 16 hr, the infected cultures were frozen and thawed; then the culture fluids were assayed for virus by a plaque method. In the balance of the cultures, fresh medium was added, the cultures were incubated for 24, 48, or 72 hr, and the fluids were assayed for viral reverse transcriptase activity as indicated in the legend to Table 1. effect on the protein, DNA, or RNA synthesis of AKR,C-or AKR,C+ cells, as measured by incorporation of appropriate radioactive precursors.
The enzymatic activity of the viral reverse transcriptase was assayed by a described method (7) . In some experiments, culture fluids were concentrated 50-fold by sedimentation at 48,000 X g before assay for enzyme activity. The activity found was so high, however, that in later studies, after the specificity of the reaction was established, the culture fluids were assayed with only a low-speed sedimentation step to remove cellular debris. Viral infectivity was measured by an XC plaque assay (8) and viral group-specific (gs) antigens by the radioimmunoprecipitation inhibition assay described for the type-C murine leukemia virus p30 (gs) antigens (9) .
RESULTS AND DISCUSSION
When AKR cells, which were chronic producers of mouse leukemia virus (AKR,C+), were treated with various doses of interferon, inhibition of both reverse transcriptase activity and viral infectivity was found ( Table 1 ). The degree of inhibition observed varied directly with the concentration of interferon used. Surprisingly, even a concentration as low as 1 international mouse reference unit per ml caused a significant inhibition of infectious virus production (0.6 logio inhibition) and a possibly significant inhibition of reverse transcriptase activity (39%).
The persistence of this effect was tested (Table 2) . While the antiviral activity of interferon in AKR,C+, as measured by inhibition of vesicular stomatitis virus growth, was well preserved 24 hr after interferon treatment, it had started to decrease by 48 hr after treatment, and no significant activity was found after 72 hr. A comparable decrease in virus reverse transcriptase activity was observed when similar concentrations of interferon were used (30 units/ml). With a lower concentration of interferon (3 units/ml), a more rapid waning of antiviral activity was observed.
Data similar to those in Table 1 have been repeatedly observed by us, and in two previous reports (10, 11) , using a different assay technique for virus, similar findings could be of virus-specific protein synthesis was inhibited, we expected that the production of MLV-AKR specific proteins would also be inhibited in AKRC+ cells treated with interferon (3).
On the contrary, however, the opposite repeatedly proved to be the case (Tables 3 and 4 ). In AKR,C+ cultures, where marked inhibition of viral reverse transcriptase activity and of infectious MLV-AKR in the culture fluids was observed, intracellular p30 (gs) antigen levels were increased by 4-to 6-fold and showed a dose-response similar to that noted for reverse transcriptase activity in that three units had only a slight effect, and maximal levels of antigen were noted in cells treated with 10 or 30 units.
In two ways, these findings contrast to the reported effects of interferon treatment of virus replication (1) . In this study, cells were already producing virus for several passages preceding interferon treatment. Usually cells must be exposed to interferon for several hours before infection if an antiviral effect is to be demonstrated. In addition, no inhibition of virus-specific protein synthesis could be found after interferon treatment of AKR, C+ cells, and indeed, the concentrations of viral antigen in interferon-treated cultures exceeded those of coni rols.
One possible explanation of these findings is that a noninfectious type-C particle lacking in viral reverse transcriptase was released by interferon-treated cells. This is unlikely, however, as indicated by the results in Table 4 . In this experiment, concentrations of interferon that inhibited virus replication, as measured by decreased reverse transcriptase activity, again were associated with increased intracellular levels of viral p30 (gs) antigens; however, the level of viral antigen was decreased in the AKR culture fluid sediments used to assay reverse transcriptase activity. Since the p30 (gs) antigen was decreased in the sediments from culture fluids of the interferon-treated cells, it is unlikely that a production of noninfectious MLV-AKR particles would account for the effect of interferon on MLV-AKR production.
These results suggest that the inhibitory effect of interferon on virus production in AKR,C+ cultures is more likely to be due to an inhibitory effect on virus assembly or on virus release rather than on the mechanisms of action (inhibition of virus-directed transcription or translation) usually ascribed to interferon. This could be due to a direct action of interferon on these late steps in the replication process. One other possible explanation is that the group-specific antigens and reverse transcriptase are cell specified, and the block induced by interferon is directed against a virus-specified product necessary for maturation of the MLV-AKR.
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